Zhejiang CONBA Pharmaceutical's low P/E ratio is due to its poor earnings outlook. Shareholders accept this, anticipating no future earnings surprises. Without improvement, this will continue to hinder the share price.

The market's expectation for durable top line growth could explain the share price weakness. The company's performance last year may indicate unresolved challenges. Several warning signs could influence the company's future performance.

Zhejiang CONBA Pharmaceutical's cash and EBIT growth point to its good position to handle any potential debt. Its strong cash conversion indicates a sturdy financial stance.

Despite share price gain, progress may not be reflected in EPS. Recorded TSR loss of 2% per year over last five years hints at potential risks, despite promising shareholder returns.